Do analysts recommend PMCB or FTH?

Sensei Biotherapeutics has a consensus price target of $58.50, suggesting a potential upside of 155.24%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sensei Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, PMCB or FTH?

Nuvilex is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A $30.66M -$1.12 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is PMCB or FTH more profitable?

Nuvilex's return on equity of 2.13% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Sensei Biotherapeutics N/A -83.59% -256.50%

Do analysts prefer ATHA or PMCB?

Athira Pharma currently has a consensus target price of $4.00, indicating a potential downside of 51.34%. Given Athira Pharma's higher possible upside, equities analysts clearly believe Athira Pharma is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ATHA or PMCB?

Athira Pharma is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$96.94M -$9.68 N/A Nuvilex N/A N/A $30.66M -$1.12 N/A

Is ATHA or PMCB more profitable?

Nuvilex's return on equity of 2.13% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% Nuvilex N/A 2.13% 1.69%

Do analysts rate PYRGF or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate PMCB or GRML?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PMCB or GRML?

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A $30.66M -$1.12 N/A Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A

Is PMCB or GRML more profitable?

Nuvilex's return on equity of 2.13% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Greenland Mines Ltd. Common Stock N/A -109.40% -98.80%

Do analysts rate PMCB or LSTA?

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 350.45%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is PMCB or LSTA more profitable?

Nuvilex's return on equity of 2.13% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Lisata Therapeutics N/A -103.54% -83.08%

Nuvilex (PMCB) Competitors

$0.72 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.72 +0.00 (+0.42%)

As of 07/2/2026 06:50 PM Eastern

Compare

PMCB vs. FTH, ATHA, PYRGF, GRML, and LSTA

Should you buy Nuvilex stock or one of its competitors? MarketBeat compares Nuvilex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvilex include Sensei Biotherapeutics (FTH), Athira Pharma (ATHA), PyroGenesis Canada (PYRGF), Greenland Mines Ltd. Common Stock (GRML), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.

How does Nuvilex compare to Sensei Biotherapeutics?

Nuvilex (NASDAQ:PMCB) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Sensei Biotherapeutics had 7 more articles in the media than Nuvilex. MarketBeat recorded 7 mentions for Sensei Biotherapeutics and 0 mentions for Nuvilex. Sensei Biotherapeutics' average media sentiment score of 0.99 beat Nuvilex's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvilex	Neutral
Sensei Biotherapeutics	Positive

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nuvilex's return on equity of 2.13% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Nuvilex is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Sensei Biotherapeutics has a consensus price target of $58.50, suggesting a potential upside of 155.24%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensei Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

Nuvilex has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market.

Summary

Nuvilex and Sensei Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Nuvilex compare to Athira Pharma?

Athira Pharma (NASDAQ:ATHA) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Athira Pharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Athira Pharma currently has a consensus target price of $4.00, indicating a potential downside of 51.34%. Given Athira Pharma's higher possible upside, equities analysts clearly believe Athira Pharma is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 19.8% of Athira Pharma shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Athira Pharma's average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Nuvilex	Neutral

Nuvilex's return on equity of 2.13% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Nuvilex	N/A	2.13%	1.69%

Athira Pharma is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Summary

Nuvilex beats Athira Pharma on 5 of the 9 factors compared between the two stocks.

How does Nuvilex compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Nuvilex (NASDAQ:PMCB) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

PyroGenesis Canada has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, PyroGenesis Canada's average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Nuvilex	Neutral

Nuvilex has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Nuvilex's return on equity of 2.13% beat PyroGenesis Canada's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Nuvilex	N/A	2.13%	1.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex has lower revenue, but higher earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Summary

Nuvilex beats PyroGenesis Canada on 8 of the 11 factors compared between the two stocks.

How does Nuvilex compare to Greenland Mines Ltd. Common Stock?

Nuvilex (NASDAQ:PMCB) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Greenland Mines Ltd. Common Stock had 2 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Greenland Mines Ltd. Common Stock and 0 mentions for Nuvilex. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.30 beat Nuvilex's score of 0.00 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvilex	Neutral
Greenland Mines Ltd. Common Stock	Neutral

Nuvilex has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 7.05, indicating that its stock price is 605% more volatile than the broader market.

Nuvilex's return on equity of 2.13% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by insiders. Comparatively, 11.3% of Greenland Mines Ltd. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nuvilex and Greenland Mines Ltd. Common Stock tied by winning 5 of the 10 factors compared between the two stocks.

How does Nuvilex compare to Lisata Therapeutics?

Nuvilex (NASDAQ:PMCB) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Nuvilex has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

In the previous week, Nuvilex's average media sentiment score of 0.00 equaled Lisata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nuvilex	Neutral
Lisata Therapeutics	Neutral

Nuvilex has higher earnings, but lower revenue than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Lisata Therapeutics	$170K	178.45	-$16.59M	-$1.86	N/A

Nuvilex's return on equity of 2.13% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Lisata Therapeutics	N/A	-103.54%	-83.08%

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 350.45%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Nuvilex beats Lisata Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.68M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.64	20.06	28.02	24.70
Price / Sales	N/A	360.34	540.55	99.42
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.09	4.32	10.96	6.46
Net Income	$30.66M	$64.45M	$3.57B	$337.01M
7 Day Performance	-7.11%	2.97%	2.12%	1.69%
1 Month Performance	2.14%	6.83%	5.25%	3.81%
1 Year Performance	-35.06%	29.07%	33.29%	23.90%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	0.8092 of 5 stars	$0.72 flat	N/A	-35.1%	$7.68M	N/A	N/A	4	Gap Up
FTH Sensei Biotherapeutics	4.4474 of 5 stars	$24.67 +0.5%	$60.00 +143.2%	N/A	$32.93M	N/A	N/A	40	News Coverage Positive News Insider Trade Gap Up
ATHA Athira Pharma	N/A	$8.22 -4.5%	$4.00 -51.3%	+148.3%	$32.42M	N/A	N/A	40
PYRGF PyroGenesis Canada	N/A	$0.14 -3.4%	N/A	-57.6%	$31.59M	$9.14M	N/A	90	Gap Up
GRML Greenland Mines Ltd. Common Stock	0.6351 of 5 stars	$0.21 -8.0%	N/A	-79.6%	$31.52M	N/A	N/A	5	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors

PMCB vs. FTH, ATHA, PYRGF, GRML, and LSTA

How does Nuvilex compare to Sensei Biotherapeutics?

Summary

How does Nuvilex compare to Athira Pharma?

Summary

How does Nuvilex compare to PyroGenesis Canada?

Summary

How does Nuvilex compare to Greenland Mines Ltd. Common Stock?

Summary

How does Nuvilex compare to Lisata Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvilex (PMCB) Competitors

PMCB vs. FTH, ATHA, PYRGF, GRML, and LSTA

How does Nuvilex compare to Sensei Biotherapeutics?

Does the media refer more to PMCB or FTH?

Do institutionals and insiders hold more shares of PMCB or FTH?

Is PMCB or FTH more profitable?

Which has stronger valuation and earnings, PMCB or FTH?

Do analysts recommend PMCB or FTH?

Which has more volatility and risk, PMCB or FTH?

Summary

How does Nuvilex compare to Athira Pharma?

Which has more volatility & risk, ATHA or PMCB?

Do analysts prefer ATHA or PMCB?

Do institutionals & insiders have more ownership in ATHA or PMCB?

Does the media favor ATHA or PMCB?

Is ATHA or PMCB more profitable?

Which has preferable valuation and earnings, ATHA or PMCB?

Summary

How does Nuvilex compare to PyroGenesis Canada?

Which has more risk and volatility, PYRGF or PMCB?

Do institutionals & insiders hold more shares of PYRGF or PMCB?

Does the media favor PYRGF or PMCB?

Is PYRGF or PMCB more profitable?

Do analysts rate PYRGF or PMCB?

Which has better earnings and valuation, PYRGF or PMCB?

Summary

How does Nuvilex compare to Greenland Mines Ltd. Common Stock?

Which has preferable earnings and valuation, PMCB or GRML?

Do analysts rate PMCB or GRML?

Does the media favor PMCB or GRML?

Which has more volatility & risk, PMCB or GRML?

Is PMCB or GRML more profitable?

Do institutionals and insiders hold more shares of PMCB or GRML?

Summary

How does Nuvilex compare to Lisata Therapeutics?

Which has more risk & volatility, PMCB or LSTA?

Does the media refer more to PMCB or LSTA?

Which has higher valuation and earnings, PMCB or LSTA?

Is PMCB or LSTA more profitable?

Do institutionals and insiders have more ownership in PMCB or LSTA?

Do analysts rate PMCB or LSTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools